相关实验视频

Updated: Jul 4, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在IASLC分级系统中,EGFR突变影响高风险早期肺腺癌的复发

Kotaro Nomura¹, Keiju Aokage², Yasunori Kaminuma^1,3,4

¹Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

International journal of clinical oncology

|February 6, 2024

概括

具有EGFR突变的高风险早期肺腺癌患者面临复发的增加,包括中枢神经系统转移. 这凸显了在这个特定的患者群体中需要向辅助治疗的需要.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
胸部外科手术胸部外科手术

背景情况:

有限的现实世界数据存在于高风险的早期肺癌中遗传异常的临床意义.
肺癌的外科手术治疗正在发展,需要更好的风险分层.
确定预后指标对于管理早期肺腺癌至关重要.

研究的目的:

根据病理指标识别早期肺腺癌的高风险患者.
阐明表皮生长因子受体突变 (EGFRm) 状态的预后影响.
分析无复发生存率 (RFS) 和总生存率 (OS) 与病理因素和EGFRm状态相关.

主要方法:

对494名患有病态I期肺腺癌的患者 (2011-2016) 的回顾性分析.
评价国际肺癌研究协会 (IASLC) 的等级和EGFR突变 (EGFRm) 状态.
多变量分析以确定RFS和OS的预后因素;分类为高风险和低风险组.

主要成果:

在IASLC3级,入侵大小>2厘米和淋巴血管入侵被确定为不良预后指标.
高风险组的EGFRm阳性患者出现复发的发病率较高,包括中枢神经系统转移.
在低风险组的EGFRm阳性和阴性患者之间没有观察到复发的显著差异.

结论:

高风险组的EGFRm阳性I期肺腺癌与复发风险增加有关,包括中枢神经系统转移.
这些发现强调了考虑EGFRm风险分层地位的重要性.
结果表明,需要为这种患者群体开发特定的辅助治疗策略.

关键词:

累计的复发率是累计的复发率.欧洲农业基金会 (EGFR) 是一个基金.肺部腺癌瘤是肺部腺癌.病理预后因素是一种病理预后因素.

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...